Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19

Article Medicine, General & Internal

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

D. M. Weinreich et al.

Summary: Recent data indicate that complications and death from Covid-19 may be related to high viral loads. In this trial involving nonhospitalized patients, a cocktail of two neutralizing monoclonal antibodies (REGN-COV2) reduced viral load, with a greater effect in patients with no immune response or high viral load at baseline. Safety outcomes were similar between REGN-COV2 dose groups and the placebo group.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Peter Chen et al.

Summary: LY-CoV555, a neutralizing antibody, showed promising results in reducing viral load, improving symptoms, and lowering the risk of hospitalization among patients with mild or moderate Covid-19. While one of the doses appeared to accelerate the decline in viral load, others did not show significant effects by day 11.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Trends in COVID-19 Risk-Adjusted Mortality Rates

Leora Horwitz et al.

Summary: A study in a three-hospital academic health system in New York showed a decrease in hospital mortality rates among COVID-19 patients, with adjusted mortality dropping from 25.6% in March to 7.6% in August. The standardized mortality ratio also decreased from 1.26 in March to 0.38 in August, indicating an improving trend in patient outcomes. These findings suggest that mortality from COVID-19 may be decreasing even after adjusting for patient characteristics.

JOURNAL OF HOSPITAL MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal